1,720,978 research outputs found
Erectile dysfunction in diabetic patients
No full textErectile dysfunction (ED) appears to be highly prevalent in diabetic patients (around 50percent at 50 years of age) and more severe than in the rest of the population. Its etiology is multifactorial in this subset of patients. ED is highly correlated to multiple vascular risk factors and can be considered as a manifestation of endothelial dysfunction in general, alerting the physician to look at underlying silent coronary bed atherosclerosis. It is also dependent on the poor control of diabetes and on the presence of its chronic complications. Because of the multiple etiologies of ED in diabetics, a multifactorial approach is warranted to get an optimal response in treating such patients: diabetes control, use of phosphodiesterase 5 inhibitors, psychosexual counseling, and choice of antihypertensive medications.
Erectile dysfunction in diabetic patients
No full textErectile dysfunction (ED) appears to be highly prevalent in diabetic patients (around 50percent at 50 years of age) and more severe than in the rest of the population. Its etiology is multifactorial in this subset of patients. ED is highly correlated to multiple vascular risk factors and can be considered as a manifestation of endothelial dysfunction in general, alerting the physician to look at underlying silent coronary bed atherosclerosis. It is also dependent on the poor control of diabetes and on the presence of its chronic complications. Because of the multiple etiologies of ED in diabetics, a multifactorial approach is warranted to get an optimal response in treating such patients: diabetes control, use of phosphodiesterase 5 inhibitors, psychosexual counseling, and choice of antihypertensive medications.
Continuous positive airway pressure and type 2 diabetes mellitus
No full textObstructive sleep apnea (OSA) is a sleep disorder, increasingly recognized. It is commonly present in obese persons, treated with continuous positive airway pressure (CPAP), being the gold standard. The disorder has been associated with diabetes mellitus and possibly related to hypoxia per se, increased sympathetic activity, disturbed hypothalamic-pituitary-adrenal axis and increased inflammatory cytokines and leptin, all of which can adversely affect both glucose metabolism and insulin sensitivity. Given this association and the presence of common risk factors, this review assessed the impact of CPAP on diabetes mellitus through various metabolic parameters including HbA1c, nocturnal glucose and insulin resistance, in addition to the effect of CPAP on the prevention of diabetes mellitus. Results have been conflicting; Randomized controlled trials are recommended to allow objective and definite conclusions. © 2012 Diabetes India.
Controversies in the management and followup of differentiated thyroid cancer: Beyond the guidelines
Full text linkThyroid cancer is among the most common endocrine malignancies. Genetic and environmental factors play an important role in the pathogenesis of differentiated thyroid cancer. Both have good prognosis but with frequent recurrences. Cancer staging is an essential prognostic part of cancer management. There are multiple controversies in the management and followup of differentiated thyroid cancer. Debate still exists with regard to the optimal surgical approach but trends toward a more conservative approach, such as lobectomy, are being more favored, especially in papillary thyroid cancer, of tumor sizes less than 4 cm, in the absence of other high-risk suggestive features. Survival of patients with well-differentiated thyroid cancer was adversely affected by lymph node metastases. Prophylactic central LN dissection did improve accuracy in staging and decrease postop TG level, but it had no effect on small-sized tumors. Conservative approach was more applied with regard to the need and dose of radioiodine given postoperatively. There have been several advancements in the management of radioiodine resistant advanced differentiated thyroid cancers. Appropriate followup is required based on risk stratification of patients postoperatively. Many studies are still ongoing in order to reach the optimal management and followup of differentiated thyroid cancer. © 2012 Hala Ahmadieh and Sami T. Azar.
Treating low high-density lipoprotein cholesterol: What is the evidence?
No full textEpidemiological studies have shown an inverse association between high-density lipoprotein cholesterol (HDL-C) and cardiovascular disease (CVD) risk. However, genetic and interventional studies have failed to consistently support this relationship. There is an increasing body of evidence that the function of HDL, including its antiatherogenic properties and its reverse cholesterol transport activity, has a greater impact on CVD risk compared with levels of HDL alone. Targeting HDL has become a growing interest. Nevertheless, raising HDL pharmacologically has failed to show a considerable, if any, impact on cardiovascular outcome. Efforts should focus on improving HDL quality in addition to raising HDL levels when developing new therapies. Ongoing and future research will help determine the most safe and effective approach to improve cardiovascular outcome and establish the safety, efficacy and impact on atherosclerosis of the emerging HDL-raising therapies. © The Author(s), 2013.
Gemfibrozil improves postprandial hypertriglyceridemia in patients with isolated low HDL
No full textAim: To assess the response of postprandial (PP) hypertriglyceridemia to genfibrozil in healthy male subjects with isolated low HDL-Cholesterol but without the metabolic syndrome (MS). Patients and methods: 14 male subjects with isolated low HDL (HDL-C ≥ 33), normal fasting triglycerides and LDL-C levels and without any feature of the MS, were studied. 13 male subjects with HDL-C 38 mg-dl served as controls. They also had normal fasting triglycerides and LDL-C levels and without any feature of the MS. The 2 groups were statistically similar with respect to age, blood pressure, BMI, body fat composition, waist circumference, waist to hip ratio, fasting insulin, fasting and PP blood sugar, baseline fasting TG level and baseline LDL-C. Postprandial TG levels were measured at 2, 4, and 6 hours following a morning meal. Ten of the patients with PP hypertriglyceridemia were treated with gemfibrozil 600 mg PO twice-day for one month. Results: Patients had markedly higher levels of the peak PP TG at 4 hours compared to controls (296.0 ± 37.7 vs. 206.7 ± 29.9 mg-dl; P 0.05) the other two postprandial levels were also higher in patients but the difference was not significant. Treatment with gemfibrozil significantly decreased the levels of fasting and postprandial TG and increased HDL-C by around 3.6 mg-dl (11.7percent) without affecting LDL-C. Conclusion: Postprandial increase in serum TG may be present in patients with isolated HDL-C without the MS. Treatment of patients with PP hypertriglyceridemia with gemfibrozil improves the low HDL-C and postprandial rise in TG. © the author(s), publisher and licensee Libertas Academica Ltd
Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus
No full textUnfortunately, the only approved medical treatment for type 1 diabetesmellitus (DM) is insulin, despite the fact that tight control cannot be reached without some serious side effects such as hypoglycemia and weight gain.More and more importance is now shifted towards developing new drugs that can reach a better glycemic control with lesser side effects. Some of these promising drugs are the glucagon-like peptides 1 (GLP-1) and their agonists, which have been FDA approved for the treatment of type 2 DM. The purpose of this article is to review all of the relevant literature on the potential role of GLP-1 in the treatment of type 1 DM. Themajor source of data acquisition includedMedline search strategies, using the words type 1 diabetes mellitus and GLP-1. Articles published in the last 20 years were screened. GLP-1 increases insulin secretion in humans with existing beta cells; it also decreases glucagon secretion, and blunts appetite. Of note, new animal studies demonstrate a role in beta cell-proliferation and decreased apoptosis. Because of all the effects mentioned above, GLP-1 seems to be a promising drug for type 1 DM treatment, but more studies are still needed before solid conclusions can be drawn. © Springer Science+Business Media, LLC 2012.Anderson MS, 2005, ANNU REV IMMUNOL, V23, P447, DOI 10.1146-annurev.immunol.23.021704.115643; Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053-j.gastro.2007.03.054; Balks HJ, 1997, J CLIN ENDOCR METAB, V82, P786, DOI 10.1210-jc.82.3.786; Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P235; Behme MT, 2003, BMC ENDOCR DISORD, V10, P1; BELL GI, 1983, NATURE, V304, P368, DOI 10.1038-304368a0; BROWN JC, 1971, CAN J BIOCHEM CELL B, V49, P255; BROWN JC, 1971, CAN J BIOCHEM CELL B, V49, P867; BROWN JC, 1970, J PHYSIOL-LONDON, V209, P57; Brubaker PL, 2004, ENDOCRINOLOGY, V145, P2653, DOI 10.1210-en.2004-0015; Burcelin R, 2008, DIABETES METAB, V34, P627, DOI 10.1016-j.diabet.2008.08.002; Creutzfeldt WOC, 1996, DIABETES CARE, V19, P580, DOI 10.2337-diacare.19.6.580; Deacon CF, 2004, DIABETES, V53, P2181, DOI 10.2337-diabetes.53.9.2181; Devendra D, 2004, BRIT MED J, V328, P750, DOI 10.1136-bmj.328.7442.750; DINNEEN S, 1995, DIABETOLOGIA, V38, P337, DOI 10.1007-BF00400639; Drucker DJ, 1999, AM J PHYSIOL-GASTR L, V276, pG79; Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073-pnas.93.15.7911; DUMOULIN V, 1995, ENDOCRINOLOGY, V136, P5182, DOI 10.1210-en.136.11.5182; Dupre J, 1997, DIABETES CARE, V20, P381; DUPRE J, 1973, J CLIN ENDOCR METAB, V37, P826; DUPRE J, 1995, DIABETES, V44, P626, DOI 10.2337-diabetes.44.6.626; Egan JM, 2003, DIABETES-METAB RES, V19, P115, DOI 10.1002-dmrr.357; ELRICK H, 1964, J CLIN ENDOCR METAB, V24, P1076; ENG J, 1992, J BIOL CHEM, V267, P7402; Faradji RN, 2008, TRANSPLANTATION, V86, P1658, DOI 10.1097-TP.0b013e31818fe448; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210-en.130.1.159; Froud T, 2008, TRANSPLANTATION, V86, P36, DOI 10.1097-TP.0b013e31817c4ab3; Ghofaili Khalid Al, 2007, Transplantation, V83, P24, DOI 10.1097-01.tp.0000251379.46596.2d; Greenbaum CJ, 2002, DIABETES, V51, P951, DOI 10.2337-diabetes.51.4.951; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056-NEJM199205143262003; Hadjiyanni I, 2008, ENDOCRINOLOGY, V149, P1338, DOI 10.1210-en.2007-1137; Holz GG, 2003, CURR MED CHEM, V10, P2471, DOI 10.2174-0929867033456648; Kielgast A, 2010, J CLIN ENDOCR METAB, V95, P2492; MADSBAD S, 1980, ACTA ENDOCRINOL-COP, V95, P359; Li YH, 2005, DIABETES, V54, P482; LICKLEY HLA, 1981, SURGERY, V90, P186; List JF, 2004, AM J PHYSIOL-ENDOC M, V286, pE875, DOI 10.1152-ajpendo.00007.2004; Liu MJ, 2010, J MOL MED-JMM, V88, P351, DOI 10.1007-s00109-009-0571-z; Loew ER, 1940, AM J PHYSIOL, V128, P0298; Loew ER, 1940, AM J PHYSIOL, V129, P0659; Loew ER, 1939, AM J PHYSIOL, V126, P270; Lopez-Delgado MI, 1998, ENDOCRINOLOGY, V139, P2811, DOI 10.1210-en.139.6.2811; Lugari R, 2000, HORM METAB RES, V32, P424, DOI 10.1055-s-2007-978665; MADSBAD S, 1983, DIABETOLOGIA, V24, P141; MATSUYAMA T, 1975, HORM METAB RES, V7, P452; MCINTYRE N, 1964, LANCET, V2, P20; Meier JJ, 2005, DIABETES-METAB RES, V21, P91, DOI 10.1002-dmrr.538; Meier JJ, 2001, DIABETES, V50, P2497, DOI 10.2337-diabetes.50.11.2497; Meier JJ, 2008, DIABETOLOGIA, V51, P703, DOI 10.1007-s00125-008-0936-9; Meneilly GS, 2003, DIABETES CARE, V26, P837, DOI 10.2337-diacare.26.3.837; MERIDA E, 1993, J CLIN ENDOCR METAB, V77, P1654, DOI 10.1210-jc.77.6.1654; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172-JCI112855; Morales M, 1997, DIABETES, V46, P1264, DOI 10.2337-diabetes.46.8.1264; NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172-JCI116186; Ogawa N, 2004, DIABETES, V53, P1700, DOI 10.2337-diabetes.53.7.1700; Perez-Arana G, 2010, ENDOCRINOLOGY, V151, P2538, DOI 10.1210-en.2009-1113; Raman VS, 2010, DIABETES CARE, V33, P1294, DOI 10.2337-dc09-1959; Rocca AS, 2001, ENDOCRINOLOGY, V142, P1148, DOI 10.1210-en.142.3.1148; Roep BO, 2007, ANN NY ACAD SCI, V1103, P1, DOI 10.1196-annals.1394.018; SAKURAI H, 1975, DIABETOLOGIA, V11, P427, DOI 10.1007-BF00429911; Schirra J, 1998, J CLIN INVEST, V101, P1421, DOI 10.1172-JCI1349; SCHMIDT WE, 1985, DIABETOLOGIA, V28, P704, DOI 10.1007-BF00291980; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038-nm1196-1254; Serre V, 1998, ENDOCRINOLOGY, V139, P4448, DOI 10.1210-en.139.11.4448; Sherry NA, 2007, ENDOCRINOLOGY, V148, P5136, DOI 10.1210-en.2007-0358; Stoffers DA, 2000, DIABETES, V49, P741, DOI 10.2337-diabetes.49.5.741; Suarez-Pinzon WL, 2008, DIABETES, V57, P3281, DOI 10.2337-db08-0688; Suen PM, 2006, INT J BIOCHEM CELL B, V38, P951, DOI 10.1016-j.biocel.2005.08.005; Thomsen C, 2003, AM J CLIN NUTR, V77, P605; Varga Timea, 2010, Orvosi Hetilap, V151, P899, DOI 10.1556-OH.2010.28842; Vella A, 2002, DIABETOLOGIA, V45, P1410, DOI 10.1007-s00125-002-0924-4; Vella A, 2001, DIABETES, V50, P565, DOI 10.2337-diabetes.50.3.565; VILLANUEVAPENACARRILLO ML, 1994, DIABETOLOGIA, V37, P1163, DOI 10.1007-BF00418382; VILLANUEVAPENACARRILLO ML, 1995, J ENDOCRINOL, V146, P183, DOI 10.1677-joe.0.1460183; Vilsboll T, 2003, J CLIN ENDOCR METAB, V88, P2706, DOI 10.1210-jc.2002-021873; Wang YH, 1997, J CLIN INVEST, V99, P2883, DOI 10.1172-JCI119482; Yang ZD, 2006, BIOCHEM BIOPH RES CO, V344, P1017, DOI 10.1016-j.bbrc.2006.03.177; Zhang J, 2007, DIABETOLOGIA, V50, P1900, DOI 10.1007-s00125-007-0737-677
The role of vitamin D deficiency in the incidence, progression, and complications of type 1 diabetes mellitus
No full textThe nonclassic role of 1,25-dihydroxyvitamin D3 (1,25(OH) 2D3) has been recently widely recognized. In type 1 diabetes mellitus (T1D), it plays an immunomodulatory role through the vitamin D receptor (VDR) present on pancreatic and immune cells. Specific VDR allelic variants have been associated with T1D in many countries. Furthermore, vitamin D deficiency has been prevalent in T1D, and the seasonal and latitude variability in the incidence of T1D can be partly explained by the related variability in vitamin D level. In fact, retrospective studies of vitamin D supplementation during pregnancy or infancy showed a lower incidence of T1D. We will review the different mechanisms of the vitamin D protective effect against insulitis and present the available data on the role of vitamin D deficiency in the control, progression, and complications of T1D. © 2013 Marlene Chakhtoura and Sami T. Azar.Aljabri KS, 2010, ANN SAUDI MED, V30, P454, DOI 10.4103-0256-4947.72265; [Anonymous], 1999, DIABETOLOGIA, V42, P51; [Anonymous], 2000, LANCET, V355, P873; Antico A, 2012, AUTOIMMUN REV, V12, P127, DOI 10.1016-j.autrev.2012.07.007; Arnson Y, 2007, ANN RHEUM DIS, V66, P1137, DOI 10.1136-ard.2007.069831; Ban Y, 2001, BMC Med Genet, V2, P7, DOI 10.1186-1471-2350-2-7; Bener A, 2009, ACTA DIABETOL, V46, P183, DOI 10.1007-s00592-008-0071-6; Bianco MG, 2004, EUR J ENDOCRINOL, V151, P641, DOI 10.1530-eje.0.1510641; Bierschenk L, 2009, DIABETES CARE, V32, P1977, DOI 10.2337-dc09-1089; Bizzarri C, 2010, DIABETES CARE, V33, P1962, DOI 10.2337-dc10-0814; BOCK T, 1994, DIABETES CARE, V17, P1154, DOI 10.2337-diacare.17.10.1154; Boraska V, 2008, J HUM GENET, V53, P210, DOI 10.1007-s10038-007-0234-2; Borkar VV, 2010, PEDIATR DIABETES, V11, P345, DOI 10.1111-j.1399-5448.2009.00589.x; Brekke HK, 2007, PEDIATR DIABETES, V8, P11, DOI 10.1111-j.1399-5448.2006.00223.x; Casu A, 2004, PEDIATR DIABETES, V5, P32, DOI 10.1111-j.1399-543X.2004.00037.x; Chang TJ, 2000, CLIN ENDOCRINOL, V52, P575, DOI 10.1046-j.1365-2265.2000.00985.x; Craig ME, 2009, PEDIATR DIABETES, V10, P3, DOI 10.1111-j.1399-5448.2009.00568.x; Cutolo M, 2011, AUTOIMMUN REV, V11, P84, DOI 10.1016-j.autrev.2011.08.003; DeLuca Hector F, 2004, Am J Clin Nutr, V80, p1689S; Devaraj S, 2011, AM J CLIN PATHOL, V135, P429, DOI 10.1309-AJCPJGZQX42BIAXL; Di Cesar DJ, 2006, DIABETES CARE, V29, P174, DOI 10.2337-diacare.29.01.06.dc05-1876; El Baba Khaled, 2011, Int J Gen Med, V4, P635, DOI 10.2147-IJGM.S23548; El Baba K, 2010, BIOL RHYTHM RES, V41, P91, DOI 10.1080-09291010802594471; Emamaullee JA, 2009, DIABETES, V58, P1302, DOI 10.2337-db08-1113; Fassbender WJ, 2002, HORM METAB RES, V34, P330, DOI 10.1055-s-2002-33262; Fichna M, 2010, INT J IMMUNOGENET, V37, P367, DOI 10.1111-j.1744-313X.2010.00935.x; Forlenza GP, 2011, CURR OPIN ENDOCRINOL, V18, P248, DOI 10.1097-MED.0b013e32834872ce; Fronczak CM, 2003, DIABETES CARE, V26, P3237, DOI 10.2337-diacare.26.12.3237; Garcia D, 2007, DIABETES RES CLIN PR, V77, P134, DOI 10.1016-j.diabres.2006.10.018; Giarratana N, 2004, J IMMUNOL, V173, P2280; Giulietti A, 2004, DIABETOLOGIA, V47, P451, DOI 10.1007-s00125-004-1329-3; Greer R. M., 2012, PEDIAT DIABETES, V14, P31; Gregori S, 2002, DIABETES, V51, P1367, DOI 10.2337-diabetes.51.5.1367; Guja C, 2002, J CELL MOL MED, V6, P75, DOI 10.1111-j.1582-4934.2002.tb00312.x; Gyorffy B, 2002, EUR J ENDOCRINOL, V147, P803, DOI 10.1530-eje.0.1470803; Gysemans CA, 2005, ENDOCRINOLOGY, V146, P1956, DOI 10.1210-en.2004-1322; Hamed EA, 2011, PEDIATR DIABETES, V12, P536, DOI 10.1111-j.1399-5448.2010.00739.x; Harris S, 2002, NUTR REV, V60, P118, DOI 10.1301-00296640260085868; Harrison LC, 2008, J AUTOIMMUN, V31, P306, DOI 10.1016-j.jaut.2008.04.026; Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210-jc.2011-0385; Huynh T, 2009, PEDIATR DIABETES, V10, P38, DOI 10.1111-j.1399-5448.2008.00439.x; Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016-S0140-6736(01)06580-1; Israni N, 2009, PLOS ONE, V4, DOI 10.1371-journal.pone.0008023; Janner M, 2010, SWISS MED WKLY, V140, DOI 10.4414-smw.2010.13091; Joner G, 2004, DIABETES CARE, V27, P1618, DOI 10.2337-diacare.27.7.1618; Jongbloet PH, 1998, DIABETES CARE, V21, P190; Judd S., 2008, CIRCULATION, V117, P503; Kalliora MI, 2011, HORM-INT J ENDOCRINO, V10, P67; Khoo AL, 2011, IMMUNOLOGY, V134, P459, DOI 10.1111-j.1365-2567.2011.03507.x; Kordonouri O, 2002, EUR J PEDIATR, V161, P291, DOI 10.1007-s00431-002-0941-9; Kriegel MA, 2011, SEMIN ARTHRITIS RHEU, V40, P512, DOI 10.1016-j.semarthrit.2010.07.009; Lammi N, 2007, DIABETOLOGIA, V50, P1393, DOI 10.1007-s00125-007-0690-4; Laron Z, 2005, ISRAEL MED ASSOC J, V7, P381; LEE S, 1994, ENDOCRINOLOGY, V134, P1602, DOI 10.1210-en.134.4.1602; Lemos MC, 2008, HUM IMMUNOL, V69, P134, DOI 10.1016-j.humimm.2008.01.008; Li X, 2009, DIABETES-METAB RES, V25, P411, DOI 10.1002-dmrr.977; Littorin B, 2006, DIABETOLOGIA, V49, P2847, DOI 10.1007-s00125-006-0426-x; Marjamaki L, 2010, DIABETOLOGIA, V53, P1599, DOI 10.1007-s00125-010-1734-8; Marti G, 2004, MED CLIN-BARCELONA, V123, P286; MATHIEU C, 1992, DIABETES, V41, P1491, DOI 10.2337-diabetes.41.11.1491; MATHIEU C, 1994, DIABETOLOGIA, V37, P552, DOI 10.1007-BF00403372; MATHIEU C, 1995, ENDOCRINOLOGY, V136, P866, DOI 10.1210-en.136.3.866; McDermott MF, 1997, DIABETOLOGIA, V40, P971, DOI 10.1007-s001250050776; Merriman TR, 2009, DIABETES RES CLIN PR, V83, P149, DOI 10.1016-j.diabres.2008.11.010; Mimbacas A, 2007, GENET MOL RES, V6, P534; Mohammadnejad Z, 2012, MOL BIOL REP, V39, P831, DOI 10.1007-s11033-011-0805-3; Mohr SB, 2008, DIABETOLOGIA, V51, P1391, DOI 10.1007-s00125-008-1061-5; Moroni L, 2012, AUTOIMMUN REV, V11, pA386, DOI 10.1016-j.autrev.2011.11.012; Mory DB, 2009, HUM IMMUNOL, V70, P447, DOI 10.1016-j.humimm.2009.03.007; Nagpal S, 2005, ENDOCR REV, V26, P662, DOI 10.1210-er.2004-0002; Nejentsev S, 2004, DIABETES, V53, P2709, DOI 10.2337-diabetes.53.10.2709; NYOMBA BL, 1989, ENDOCRINOLOGY, V124, P565; NYSTROM L, 1992, INT J EPIDEMIOL, V21, P352, DOI 10.1093-ije-21.2.352; Ogunkolade BW, 2002, DIABETES, V51, P2294, DOI 10.2337-diabetes.51.7.2294; Overbergh L, 2000, DIABETES, V49, P1301, DOI 10.2337-diabetes.49.8.1301; Pani MA, 2000, DIABETES, V49, P504, DOI 10.2337-diabetes.49.3.504; Panierakis C, 2009, CLIN IMMUNOL, V133, P276, DOI 10.1016-j.clim.2009.08.004; Penna G, 2000, J IMMUNOL, V164, P2405; Piemonti L, 2000, J IMMUNOL, V164, P4443; Pitocco D, 2006, DIABETIC MED, V23, P920, DOI 10.1111-j.1464-5491.2006.01921.x; Ponsonby AL, 2008, AM J EPIDEMIOL, V168, P358, DOI 10.1093-aje-kwn142; Pozzilli P, 2005, HORM METAB RES, V37, P680, DOI 10.1055-s-870578; Ramos-Lopez E, 2006, ANN NY ACAD SCI, V1079, P327, DOI 10.1196-annals.1375.050; Reis AF, 2005, DIABETES METAB, V31, P318, DOI 10.1016-S1262-3636(07)70200-8; Riachy R, 2002, ENDOCRINOLOGY, V143, P4809, DOI 10.1210-en.2002-220449; Riachy R, 2001, J ENDOCRINOL, V169, P161, DOI 10.1677-joe.0.1690161; Riachy R, 2006, APOPTOSIS, V11, P151, DOI 10.1007-s10495-006-3558-z; Roche EF, 2003, J PEDIATR ENDOCR MET, V16, P779; RODLAND O, 1985, DIABETOLOGIA, V28, P663, DOI 10.1007-BF00291972; Ross A Catharine, 2011, J Clin Endocrinol Metab, V96, P53, DOI 10.1210-jc.2010-2704; Rothwell PM, 1996, BRIT MED J, V312, P1456; Rothwell PM, 1999, BRIT MED J, V319, P887; Sahin SB, 2012, GENET TEST MOL BIOMA, V16, P1179, DOI 10.1089-gtmb.2012.0173; Samuelsson U, 1999, ARCH DIS CHILD, V81, P143; Savinov AY, 2003, P NATL ACAD SCI USA, V100, P628, DOI 10.1073-pnas.0237359100; Shimada A, 2008, J AUTOIMMUN, V30, P207, DOI 10.1016-j.jaut.2007.09.002; Songini M, 2001, J PEDIATR ENDOCR MET, V14, P781; Staples JA, 2003, ENVIRON HEALTH PERSP, V111, P518, DOI 10.1289-ehp.5941; Stene LC, 2000, DIABETOLOGIA, V43, P1093, DOI 10.1007-s001250051499; Stene LC, 2003, AM J CLIN NUTR, V78, P1128; Svoren BM, 2009, J PEDIATR, V154, P132, DOI 10.1016-j.jpeds.2008.07.015; Tenconi MT, 2007, ACTA DIABETOL, V44, P14, DOI 10.1007-s00592-007-0235-9; Thrailkill KM, 2011, J CLIN ENDOCR METAB, V96, P142, DOI 10.1210-jc.2010-0980; Turpeinen H, 2003, EUR J ENDOCRINOL, V149, P591, DOI 10.1530-eje.0.1490591; Uitterlinden AG, 2004, GENE, V338, P143, DOI 10.1016-j.gene.2004.05.014; Ursic-Bratina N, 2001, J PEDIATR ENDOCR MET, V14, P47; Vaiserman AM, 2007, DIABETOLOGIA, V50, P32, DOI 10.1007-s00125-006-0456-4; van Etten E, 2007, EUR J IMMUNOL, V37, P395, DOI 10.1002-eji.200636043; van Etten E, 2005, J STEROID BIOCHEM, V97, P93, DOI 10.1016-j.jsbmb.2005.06.002; Verrotti A, 1999, J ENDOCRINOL INVEST, V22, P198; Wagner CL, 2008, PEDIATRICS, V122, P1142, DOI 10.1542-peds.2008-1862; Willis JA, 2002, J PEDIATR ENDOCR MET, V15, P645; Yang Z, 1998, DIABETES CARE, V21, P525, DOI 10.2337-diacare.21.4.525; Yavuz DG, 2011, ACTA DIABETOL, V48, P329, DOI 10.1007-s00592-011-0284-y; Zella JB, 2003, ARCH BIOCHEM BIOPHYS, V417, P77, DOI 10.1016-S0003-9861(03)00338-2; Zemunik T, 2005, J MOL DIAGN, V7, P600, DOI 10.1016-S1525-1578(10)60593-4; Zhang J, 2012, MOL CELL ENDOCRINOL, V355, P135, DOI 10.1016-j.mce.2012.02.003; Zipitis CS, 2008, ARCH DIS CHILD, V93, P512, DOI 10.1136-adc.2007.12857998
Connecting the lines between hypogonadism and atherosclerosis
No full textEpidemiological studies show that atherosclerotic cardiovascular disease is a leading cause of morbidity and mortality worldwide and point to gender differences with ageing males being at highest risk. Atherosclerosis is a complex process that has several risk factors and mediators. Hypogonadism is a commonly undiagnosed disease that has been associated with many of the events, and risk factors leading to atherosclerosis. The mechanistic relations between testosterone levels, atherosclerotic events, and risk factors are poorly understood in many instances, but the links are clear. In this paper, we summarize the research journey that explains the link between hypogonadism, each of the atherosclerotic events, and risk factors. We look into the different areas from which lessons could be learned, including epidemiological studies, animal and laboratory experiments, studies on androgen deprivation therapy patients, and studies on testosterone-treated patients. We finish by providing recommendations for the clinician and needs for future research. Copyright © 2012 Akl C. Fahed et al.Adiels M, 2008, ARTERIOSCL THROM VAS, V28, P1225, DOI 10.1161-ATVBAHA.107.160192; Akishita M, 2007, HYPERTENS RES, V30, P1029, DOI 10.1291-hypres.30.1029; Alexandersen P, 1999, CIRC RES, V84, P813; Ariyo AA, 2003, NEW ENGL J MED, V349, P2108, DOI 10.1056-NEJMoa001066; Aversa A, 2010, J SEX MED, V7, P3495, DOI 10.1111-j.1743-6109.2010.01931.x; BARRETTCONNOR E, 1992, ANN INTERN MED, V117, P807; Basaria S, 2010, J CLIN ENDOCR METAB, V95, P1533, DOI 10.1210-jc.2009-1579; Bhatia V, 2006, DIABETES CARE, V29, P2289, DOI 10.2337-dc06-0637; Bolla M, 1997, NEW ENGL J MED, V337, P295, DOI 10.1056-NEJM199707313370502; Bourghardt J, 2010, ENDOCRINOLOGY, V151, P5428, DOI 10.1210-en.2010-0663; Boyanov M A, 2003, Aging Male, V6, P1; Brown-Sequard C., 1889, LANCET, V134, P105; Cakir E, 2005, J CLIN ENDOCR METAB, V90, P1651, DOI 10.1210-jc.2004-2045; Calof OM, 2005, J GERONTOL A-BIOL, V60, P1451; Caminiti G, 2009, J AM COLL CARDIOL, V54, P919, DOI 10.1016-j.jacc.2009.04.078; Choong K, 2010, AGING MALE, V13, P1, DOI 10.3109-13685530903410625; Cornoldi A, 2010, INT J CARDIOL, V142, P50, DOI 10.1016-j.ijcard.2008.12.107; Ding EL, 2009, NEW ENGL J MED, V361, P1152, DOI 10.1056-NEJMoa0804381; Ding EL, 2006, JAMA-J AM MED ASSOC, V295, P1288, DOI 10.1001-jama.295.11.1288; Ezaki K, 2010, CIRC J, V74, P2448, DOI 10.1253-circj.CJ-10-0221; Fernandez-Balsells MM, 2010, J CLIN ENDOCR METAB, V95, P2560, DOI 10.1210-jc.2009-2575; Foresta C, 2006, J CLIN ENDOCR METAB, V91, P4599, DOI 10.1210-jc.2006-0763; Foresta C, 2008, CLIN ENDOCRINOL, V68, P284, DOI 10.1111-j.1365-2265.2007.03036.x; Freeman ER, 2001, J UROLOGY, V165, P371, DOI 10.1097-00005392-200102000-00004; Fu L, 2008, ASIAN J ANDROL, V10, P214, DOI 10.1111-j.1745-7262.2008.00335.x; Gustafson B, 2007, ARTERIOSCL THROM VAS, V27, P2276, DOI 10.1161-ATVBAHA.107.147835; Haddad RM, 2007, MAYO CLIN PROC, V82, P29; HAFFNER SM, 1993, J CLIN ENDOCR METAB, V77, P1610, DOI 10.1210-jc.77.6.1610; Haidar A, 2007, AGING MALE, V10, P189, DOI 10.1080-13685530701653538; Hak AE, 2002, J CLIN ENDOCR METAB, V87, P3632, DOI 10.1210-jc.87.8.3632; Hanke H, 2001, CIRCULATION, V103, P1382; Hatakeyama H, 2002, FEBS LETT, V530, P129, DOI 10.1016-S0014-5793(02)03440-3; Heitzer T, 2001, CIRCULATION, V104, P2673, DOI 10.1161-hc4601.099485; Heufelder AE, 2009, J ANDROL, V30, P726, DOI 10.2164-jandrol.108.007005; Hougaku H, 2006, AM J PHYSIOL-ENDOC M, V290, pE234, DOI 10.1152-ajpendo.00059.2005; Isidori AM, 2005, CLIN ENDOCRINOL, V63, P280, DOI 10.1111-j.1365-2265.2005.02339.x; JAFFE MD, 1977, BRIT HEART J, V39, P1217; Johnsen SH, 2005, CIRCULATION, V112, P498, DOI 10.1161-CIRCULATIONAHA.104.522706; Jones TH, 2011, DIABETES CARE, V34, P828, DOI 10.2337-dc10-1233; Jones TH, 2009, ATHEROSCLEROSIS, V207, P318, DOI 10.1016-j.atherosclerosis.2009.04.016; Kalinchenko SY, 2010, CLIN ENDOCRINOL, V73, P602, DOI 10.1111-j.1365-2265.2010.03845.x; Kang SM, 2002, AM J CARDIOL, V89, P862, DOI 10.1016-S0002-9149(02)02202-6; Kaplan SA, 2010, AGING MALE, V13, P40, DOI 10.3109-13685530903536676; Kapoor D, 2007, EUR J ENDOCRINOL, V156, P595, DOI 10.1530-EJE-06-0737; Kapoor D, 2006, EUR J ENDOCRINOL, V154, P899, DOI 10.1530-eje.1.02166; Keating NL, 2006, J CLIN ONCOL, V24, P4448, DOI 10.1200-JCO.2006.06.2497; Kenny AM, 2002, J GERONTOL A-BIOL, V57, pM460; Keymel S, 2008, BASIC RES CARDIOL, V103, P582, DOI 10.1007-s00395-008-0742-z; Kumanov P, 2007, INT J ANDROL, V30, P41, DOI 10.1111-j.1365-2605.2006.00706.x; Kumanov P, 2002, ANDROLOGIA, V34, P29, DOI 10.1046-j.1439-0272.2002.00468.x; Laaksonen DE, 2005, J CLIN ENDOCR METAB, V90, P712, DOI 10.1210-jc.2004-0970; Laaksonen DE, 2003, EUR J ENDOCRINOL, V149, P601, DOI 10.1530-eje.0.1490601; Laaksonen DE, 2004, DIABETES CARE, V27, P1036, DOI 10.2337-diacare.27.5.1036; Leifke E, 2008, HORM METAB RES, V40, P56, DOI 10.1055-s-2007-1004529; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016-0002-8703(86)90155-9; Lesser MA, 1942, NEW ENGL J MED, V226, P51, DOI 10.1056-NEJM194201082260203; LESSER MA, 1946, J CLIN ENDOCR METAB, V6, P549; Ling SH, 2002, ENDOCRINOLOGY, V143, P1119, DOI 10.1210-en.143.3.1119; Liva SM, 2001, J IMMUNOL, V167, P2060; Ly LP, 2001, J CLIN ENDOCR METAB, V86, P4078, DOI 10.1210-jc.86.9.4078; Malkin CJ, 2010, CURR OPIN ENDOCRINOL, V17, P262, DOI 10.1097-MED.0b013e328339543e; Malkin CJ, 2004, J CLIN ENDOCR METAB, V89, P3313, DOI 10.1210-jc.2003-031069; Maravelias C, 2005, TOXICOL LETT, V158, P167, DOI 10.1016-j.toxlet.2005.06.005; Mårin P, 1993, Obes Res, V1, P245; Marin R, 1999, BIOL REPROD, V61, P1012, DOI 10.1095-biolreprod61.4.1012; Mathur A, 2009, EUR J ENDOCRINOL, V161, P443, DOI 10.1530-EJE-09-0092; Mattace-Raso FUS, 2006, CIRCULATION, V113, P657, DOI 10.1161-CIRCULATIONAHA.105.555235; McCrohon JA, 2000, CIRCULATION, V101, P224; Mercuro G, 2010, J CARDIOVASC MED, V11, P207, DOI 10.2459-JCM.0b013e32833178ed; Morimoto S, 2005, J ENDOCRINOL, V187, P217, DOI 10.1677-joe.1.06357; Muller M, 2005, J CLIN ENDOCR METAB, V90, P2618, DOI 10.1210-jc.2004-1158; Muller M, 2004, CIRCULATION, V109, P2074, DOI 10.1161-01.CIR.0000125854.51637.06; Naharci Mehmet Ilkin, 2007, Endocr Pract, V13, P629; Nettleship JE, 2007, CIRCULATION, V116, P2427, DOI 10.1161-CIRCULATIONAHA.107.708768; Ng MKC, 2002, ARTERIOSCL THROM VAS, V22, P1136, DOI 10.1161-01.ATV.0000022167.80130.A6; Niskanen L, 2004, DIABETES OBES METAB, V6, P208, DOI 10.1111-j.1462-8902.2004.00335.x; Pearson LJ, 2008, PEPTIDES, V29, P1057, DOI 10.1016-j.peptides.2008.02.003; Pritchard J, 1998, J CLIN ENDOCR METAB, V83, P3277, DOI 10.1210-jc.83.9.3277; Qiu Y, 2010, ENDOCRINOLOGY, V151, P3307, DOI 10.1210-en.2009-1268; Rajala Ulla M, 2007, Diabetes Care, V30, pe13, DOI 10.2337-dc06-1979; Saad F, 2011, J OBES; Schroeder ET, 2004, J CLIN ENDOCR METAB, V89, P4863, DOI 10.1210-jc.2004-0784; Schwartz BG, 2009, INT J IMPOT RES, V21, P327, DOI 10.1038-ijir.2009.38; Selvin E, 2007, DIABETES CARE, V30, P234, DOI 10.2337-dc06-1579; Shabsigh R, 2009, INT J IMPOT RES, V21, P9, DOI 10.1038-ijir.2008.31; Shahinian VB, 2005, CANCER-AM CANCER SOC, V103, P1615, DOI 10.1002-cncr.20955; Simon D, 1997, J CLIN ENDOCR METAB, V82, P682, DOI 10.1210-jc.82.2.682; Smith Matthew R, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P247, DOI 10.1097-MED.0b013e32814db88c; Svartberg J, 2004, EUR J ENDOCRINOL, V150, P65, DOI 10.1530-eje.0.1500065; WU SZ, 1993, CHINESE MED J-PEKING, V106, P415; TENOVER JS, 1992, J CLIN ENDOCR METAB, V75, P1092, DOI 10.1210-jc.75.4.1092; Tharp DL, 2009, CARDIOVASC RES, V82, P152, DOI 10.1093-cvr-cvp038; THOMPSON PD, 1989, JAMA-J AM MED ASSOC, V261, P1165, DOI 10.1001-jama.261.8.1165; Tomaszewski M, 2009, ATHEROSCLEROSIS, V203, P257, DOI 10.1016-j.atherosclerosis.2008.06.002; Traish AM, 2009, VASC PHARMACOL, V51, P303, DOI 10.1016-j.vph.2009.09.003; Traish AM, 2009, FEBS J, V276, P5755, DOI 10.1111-j.1742-4658.2009.07305.x; Traish AM, 2009, J ANDROL, V30, P23, DOI 10.2164-jandrol.108.005751; Uyanik BS, 1997, JPN HEART J, V38, P73; Van Pottelbergh I, 2003, ATHEROSCLEROSIS, V166, P95, DOI 10.1016-S0021-9150(02)00308-8; Vignozzi L, 2007, J SEX MED, V4, P620, DOI 10.1111-j.1743-6109.2007.00440.x; Walker TC, 1942, J CLIN ENDOCRINOL, V2, P560; WHO, 2011, GLOB STAT REP NONC D; Yeap BB, 2010, CURR OPIN ENDOCRINOL, V17, P269, DOI 10.1097-MED.0b013e3283383031; Zgliczynski S, 1996, ATHEROSCLEROSIS, V121, P35, DOI 10.1016-0021-9150(95)05673-4; Zitzmann M, 2007, J CLIN ENDOCR METAB, V92, P3844, DOI 10.1210-jc.2007-0620; Zitzmann M, 2008, J ANDROL, P54; Zitzmann M, 2002, J CLIN ENDOCR METAB, V87, P5030, DOI 10.1210-jc.2002-020504; Zumoff B, 2003, METABOLISM, V52, P1126, DOI 10.1016-S0026-0495(03)00186-078
The link between thyroid function and depression
No full textThe relation between thyroid function and depression has long been recognized. Patients with thyroid disorders are more prone to develop depressive symptoms and conversely depression may be accompanied by various subtle thyroid abnormalities. Traditionally, the most commonly documented abnormalities are elevated T4 levels, low T3, elevated rT3, a blunted TSH response to TRH, positive antithyroid antibodies, and elevated CSF TRH concentrations. In addition, thyroid hormone supplements appear to accelerate and enhance the clinical response to antidepressant drugs. However, the mechanisms underlying the interaction between thyroid function and depression remain to be further clarified. Recently, advances in biochemical, genetic, and neuroimaging fields have provided new insights into the thyroid-depression relationship. © 2012 Mirella P. Hage and Sami T. Azar.1
- …
